Biodexa Pharmaceticals (BDRX)

Biodexa Pharmaceticals (BDRX) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $860,974; returns 1 day +2.2%, 1 week -7.2%, 1 year -98.8%.

Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) is a clinical-stage biopharmaceutical company focused on developing innovative treatments for diseases with high unmet medical needs, utilizing proprietary drug delivery technologies like Q-Sphera, MidaSolve, and MidaCore. Its primary revenue generation, though currently minimal, stems from research and development collaborations, notably with Janssen.

Groups BDRX belongs to

• Healthcare
• Biotechnology
• Recent Reverse Splits
• United Kingdom Companies
• Biopharmaceutical
• Clinical Stage
• Clinical Stage Biotech
• Drug Discovery
• Rare Diseases
• Unmet Medical Needs
• Oncology
• Fast Track Designation
• Type 1 Diabetes
• Pharmaceuticals

BDRX financial model: income statement, cash flow and balance sheet